Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women

Carcinogenesis

Volumn 30, Issue 2, 2009, Pages 269-274

  Rebbeck, Timothy R ^a,b   Demichele, Angela ^a,b   Tran, Teo V ^b   Panossian, Saarene ^b   Bunin, Greta R ^b,c   Troxel, Andrea B ^a,b   Strom, Brian L ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE 1; PROGESTERONE RECEPTOR;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; EUROPEAN AMERICAN; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POPULATION BASED CASE CONTROL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL;

AFRICAN AMERICANS; AGED; BREAST NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HUMANS; MAP KINASE KINASE KINASE 1; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; RECEPTOR, ERBB-2; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 60149098584     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgn247     Document Type: Article

References (36)

1. Easton,D.F. et al. (2007) Genome-wide association study identifies novel breast cancer susceptibility loci. Nature, 447, 1087-1093.
2. Hunter,D.J. et al. (2007) A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat. Genet., 39, 870-874.
3. Watters,J.J. et al. (1997) Rapid membrane effects of steroids in neuroblastoma cells: Effects of estrogen on mitogen activated protein kinase signalling cascade and c-fos immediate early gene transcription. Endocrinology, 138, 4030-4033.
4. Klinge,C.M. et al. (2005) Resveratrol and estradiol rapidly activate MAPK signaling through estrogen receptors alpha and beta in endothelial cells. J. Biol. Chem., 280, 7460-7468.
5. Grose,R. et al. (2005) Fibroblast growth factor signaling in tumorigenesis. Cytokine Growth Factor Rev., 16, 179-186.
6. Moffa,A.B. et al. (2007) Differential signal transduction of alternatively spliced FGFR2 variants expressed in human mammary epithelial cells. J. Cell Physiol., 210, 720-731.
7. Koziczak,M. et al. (2004) Blocking of FGFR signaling inhibits breast cancer cell proliferation through downregulation of D-type cyclins. Oncogene, 23, 3501-3508.
8. Lu,P. et al. (2008) Genetic mosaic analysis reveals FGF receptor 2 function in terminal end buds during mammary gland branching morphogenesis. Dev. Biol., 321, 77-87.
9. Raskin,L. et al. (2008) FGFR2 is a breast cancer susceptibility gene in Jewish and Arab Israeli populations. Cancer Epidemiol. Biomarkers Prev., 17, 1060-1065.
10. Carroll,J.S. et al. (2006) Genome-wide analysis of estrogen receptor binding sites. Nat. Genet., 38, 1289-1297.
11. Garcia-Closas,M. et al. (2008) Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet., 4, e1000054.
12. Stacey,S.N. et al. (2008) Common variants on chromosome 5p12 confer susceptibility to estrogen receptor-positive breast cancer. Nat. Genet., 40, 703-6.
13. Nordgard,S.H. et al. (2007) Genes harbouring susceptibility SNPs are differentially expressed in the breast cancer subtypes. Breast Cancer Res., 9, 113.
14. Meyer,K.B. et al. (2008) Allele-specific up-regulation of FGFR2 increases susceptibility to breast cancer. PLoS Biol., 6, e108.
15. Bild,A.H. et al. (2006) Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature, 439, 353-357.
16. Creighton,C.J. et al. (2006) Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors. Cancer Res., 66 3903-3911.
17. Key,T.J. et al. (2001) Epidemiology of breast cancer. Lancet Oncol., 2, 133-140.
18. Rebbeck,T.R. et al. (2006) Estrogen sulfation genes, hormone replacement therapy, and endometrial cancer risk. J. Natl Cancer Inst., 98, 1311-1320.
19. Bunin,G.R. et al. (2005) Practical aspects of sharing controls between case-control studies. Pharmacoepidemiol. Drug Saf., 14 523-530.
20. Strom,B.L. et al. (2006) Case-control study of postmenopausal hormone replacement therapy and endometrial cancer. Am. J. Epidemiol. 164, 775-786.
21. Rebbeck,T.R. et al. (2007) A retrospective case-control study of the use of hormone-related supplements and association with breast cancer. Int. J. Cancer, 120, 1523-1528.
22. Wells,G. et al. (2002) Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women. Endocr. Rev., 23, 529-539.
23. Grady,D. et al. (2000) Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann. Intern. Med., 132, 689-696.
24. Grady,D. et al. (2002) Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA, 288, 49-57.
25. Beral,V. et al. (2002) Evidence from randomised trials on the long-term effects of hormone replacement therapy. Lancet, 360 942-944.
26. Hulley,S. et al. (1998) Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA, 280, 605-613.
27. Simon,J.A. et al. (2001) Postmenopausal hormone therapy and risk of stroke: The Heart and Estrogen-progestin Replacement Study (HERS). Circulation, 103, 638-642.
28. Rossouw,J.E. et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288, 321-333.
29. Rossouw,J.E. et al. (1996) Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA, 275, 370-375.
30. Marrett,L.D. et al. (1982) Trends in the incidence of cancer of the corpus uteri in Connecticut, 1964-1979, in relation to consumption of exogenous estrogens. Am. J. Epidemiol., 116, 57-67.
31. Lyon,J.L. et al. (1977) The rising frequency of hysterectomy: Its effect on uterine cancer rates. Am. J. Epidemiol., 105, 439-443.
32. Grady,D. et al. (1995) Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet. Gynecol., 85, 304-313.
33. Paterson,M.E. et al. (1980) Endometrial disease after treatment with oestrogens and progestogens in the climacteric. Br. Med. J., 280, 822-824.
34. Russo,J. et al. (2003) Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J. Steroid Biochem. Mol. Biol., 87, 1-25.
35. Liehr,J.G. (1990) Genotoxic effects of estrogens. Mutat. Res., 238, 269-276.
36. Tran,M.A. et al. (2008) Combining nanoliposomal ceramide with sorafenib synergistically inhibits melanoma and breast cancer cell survival to decrease tumor development. Clin. Cancer Res., 14 3571-3581.